We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Orexin Receptors

Orexin receptor antagonists block orexin receptors 1 and 2 (OX1, OX2), which respond to orexin neuropeptides. Orexin A and orexin B were described in 1998 as hypothalamic peptides that act on these two G protein-coupled receptors. In 1999 a mutation in the orexin receptor 2 gene was found to cause canine narcolepsy. Mice lacking orexin showed a narcolepsy-like phenotype in the same year, linking the system to sleep and wakefulness. OX1 is also studied in reward, addiction and stress, and OX2 mainly in arousal. SB 334867, SB-408124 and GSK1059865 are OX1-selective antagonists, and MK-3697 targets OX2. Almorexant, TCS 1102 and nemorexant are dual antagonists that block both orexin receptors.

1 Item

  • Orexin receptor modulator-1
    Cat. No.
    A62734
    CAS No.
    2125735-57-9

    Orexin receptor modulator-1

    Orexin receptor modulator-1 is a selective modulator of orexin receptors, playing a vital role in the regulation of arousal, wakefulness, and appetite. It demonstrates significant biological activity in the context of substance addiction, anxiety, depression, and various stress-related disorders. This compound serves as a valuable tool for investigating the pathophysiology of disorders such as post-traumatic stress disorder, panic disorder, and seasonal affective disorder, as well as the modulation of pain and hypertension.

    In stock View Details
    5 mg
    $350.00
    10 mg
    $650.00
    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...